PMID- 35116338
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 11
DP  - 2021 Nov
TI  - YBX1 promotes tumor progression via the PI3K/AKT signaling pathway in laryngeal 
      squamous cell carcinoma.
PG  - 4859-4869
LID - 10.21037/tcr-21-2087 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the most commonly 
      seen malignancies of the head and neck, with increasing incidence and mortality. 
      The Y-box-binding protein 1 (YBX1) is a type of oncoprotein which is related to 
      the malignant phenotype of many cancers. It is reported that YBX1 could regulate 
      tumorigenesis, recurrence, and metastasis in multiple cancers. However, little is 
      known about its carcinogenic function and mechanism in LSCC. METHODS: Firstly, 
      Through Oncomine StarBase, we found that the YBX1 mRNA level was increased in a 
      variety of cancer tissues, including in the LSCC, compared with normal tissues. 
      We silenced YBX1 in LSCC cells using short hairpin RNAs (shRNAs). Secondly, the 
      biological function of YBX1 in LSCC cells was examined by the Cell Counting Kit-8 
      (CCK-8) assay, flow cytometry, the wound healing assay, and the transwell assay. 
      Thirdly, the correlation between YBX1 and the PI3K/AKT pathway was verified by 
      the western blot assay. RESULTS: Expression of YBX1 is higher in a variety of 
      cancer tissues, especially in the head and neck cancers. After transfected with 
      lentiviral vectors, the expression of YBX1 was significantly silenced. 
      Functionally, low expression of YBX1 promoted LSCC cell apoptosis and inhibited 
      LSCC cell proliferation, migration, and invasion. The transfection of sh-YBX1 
      resulted in an obvious decrease in PI3K/AKT signaling molecules in LSCC cells. 
      CONCLUSIONS: We demonstrated that YBX1 could promote LSCC cell progression 
      through the PI3K/AKT pathway, providing new insights into a potential biomarker 
      and target for LSCC treatment.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Department of Otolaryngology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Department of Otolaryngology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Otolaryngology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797748
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma (LSCC)
OT  - PI3K/AKT
OT  - YBX1
OT  - cancer promoter
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at https://dx.doi.org/10.21037/tcr-21-2087). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/11/01
CRDT- 2022/02/04 05:48
PHST- 2021/09/09 00:00 [received]
PHST- 2021/11/03 00:00 [accepted]
PHST- 2022/02/04 05:48 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - tcr-10-11-4859 [pii]
AID - 10.21037/tcr-21-2087 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 Nov;10(11):4859-4869. doi: 10.21037/tcr-21-2087.